Nu Skin Enterprises, Inc. NUS
We take great care to ensure that the data presented and summarized in this overview for NU SKIN ENTERPRISES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NUS
View all-
Black Rock Inc. New York, NY8.12MShares$46.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.94MShares$22.5 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.25MShares$12.9 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.68MShares$9.61 Million0.02% of portfolio
-
Hotchkis & Wiley Capital Management LLC Los Angeles, CA1.58MShares$9.01 Million0.04% of portfolio
-
Morgan Stanley New York, NY1.23MShares$7.06 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY1.23MShares$7.05 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.12MShares$6.43 Million0.0% of portfolio
-
State Street Corp Boston, MA1.12MShares$6.39 Million0.0% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA1.02MShares$5.86 Million0.02% of portfolio
Latest Institutional Activity in NUS
Top Purchases
Top Sells
About NUS
Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
Insider Transactions at NUS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 05
2025
|
Justin S Keisel EVP, President of Global Sales |
BUY
Small Acquisition
|
Direct |
48
+0.05%
|
$336
$7.44 P/Share
|
|
Mar 05
2025
|
Edwina D Woodbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
12
+0.04%
|
$96
$8.16 P/Share
|
|
Feb 26
2025
|
Chayce David Clark EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
113,196
+30.88%
|
-
|
|
Feb 26
2025
|
Steven Keith Hatchett Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
64,684
+29.37%
|
-
|
|
Feb 26
2025
|
Justin S Keisel EVP, President of Global Sales |
BUY
Grant, award, or other acquisition
|
Direct |
51,747
+36.31%
|
-
|
|
Feb 26
2025
|
Ryan S Napierski President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
310,479
+32.55%
|
-
|
|
Feb 26
2025
|
James D Thomas Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,152
+34.29%
|
-
|
|
Feb 21
2025
|
Emma S. Battle Director |
SELL
Open market or private sale
|
Direct |
1,693
-8.81%
|
$11,851
$7.73 P/Share
|
|
Feb 15
2025
|
Justin S Keisel EVP, President of Global Sales |
SELL
Payment of exercise price or tax liability
|
Direct |
5,552
-12.46%
|
$38,864
$7.56 P/Share
|
|
Feb 15
2025
|
Steven Keith Hatchett Chief Product Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,949
-8.96%
|
$62,643
$7.56 P/Share
|
|
Feb 15
2025
|
James D Thomas Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,856
-14.27%
|
$75,992
$7.56 P/Share
|
|
Feb 15
2025
|
Chayce David Clark EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
14,227
-9.22%
|
$99,589
$7.56 P/Share
|
|
Feb 15
2025
|
Ryan S Napierski President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
40,857
-10.93%
|
$285,999
$7.56 P/Share
|
|
Feb 12
2025
|
Justin S Keisel EVP, President of Global Sales |
BUY
Grant, award, or other acquisition
|
Direct |
1,198
+2.62%
|
-
|
|
Feb 12
2025
|
Chayce David Clark EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
6,451
+4.01%
|
-
|
|
Feb 12
2025
|
Steven Keith Hatchett Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,686
+3.56%
|
-
|
|
Feb 12
2025
|
James D Thomas Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,055
+5.06%
|
-
|
|
Feb 12
2025
|
Ryan S Napierski President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
17,694
+4.52%
|
-
|
|
Dec 20
2024
|
Chayce David Clark EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
9,070
-5.78%
|
$54,420
$6.6 P/Share
|
|
Dec 11
2024
|
Justin S Keisel EVP, President of Global Sales |
BUY
Small Acquisition
|
Direct |
47
+0.05%
|
$329
$7.62 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 728K shares |
|---|---|
| Small Acquisition | 173 shares |
| Open market or private sale | 5.39K shares |
|---|---|
| Payment of exercise price or tax liability | 92.8K shares |